X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquired assets include NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation. It is an orally administered novel small molecule that inhibits inflammation-driven insulin resistance and major pathological inflammatory cascades.
Lead Product(s): 17α-ethynyl-androst-5-ene-3,7,17-triol
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioVie
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 11, 2021
Details:
NeurMedix’s lead clinical drug candidate, NE3107, 17α-ethynyl-androst-5-ene-3,7,17-triol, is a first-in-class small molecule, orally administered, highly effective inhibitor of insulin resistance and the pathological inflammatory cascade and with a novel mechanism of action.
Lead Product(s): 17α-ethynyl-androst-5-ene-3,7,17-triol
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: BioVie
Deal Size: $3360.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 27, 2021
Details:
The trial will evaluate twice daily 20 mg oral NE3107 versus placebo for 30 weeks beginning with dose titration of 5 mg BID in weeks 1 and 2 and 10 mg BID in weeks 3-4, with 20 mg BID for weeks 5-30.
Lead Product(s): 17α-ethynyl-androst-5-ene-3,7,17-triol
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
